Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Oct 8;9(10):e70230.
doi: 10.1002/hem3.70230. eCollection 2025 Oct.

Towards personalized medicine for refractory/relapsed follicular lymphoma patients: The Lupiae-Cantera study

Irene Dogliotti  1 , Sanne Tonino  2 , Luana Conte  3   4 , Yana Stepanishyna  5 , Filipa Moita  6 , Sofia Brites Alves  6 , Ana Jiménez-Ubieto  7 , Sonia Gonzalez de Villambrosia  8 , Federica Cavallo  1 , Raquel Del Campo Garcia  9   10 , Natalia Zing  11   12 , Marie José Kersten  2 , Massimo Federico  13 ; EHA LyG Cantera 2018
Affiliations
Editorial

Towards personalized medicine for refractory/relapsed follicular lymphoma patients: The Lupiae-Cantera study

Irene Dogliotti et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The 2018 EHA LyG Cantera team (coach, assistant coach, and players).
Figure 2
Figure 2
Sankey plot describing the trends in treatments employed in first and second line (included n = 104).
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375‐2390. 10.1182/blood-2016-01-643569 - DOI - PMC - PubMed
    1. Zelenetz AD, Gordon LI, Wierda WG, et al. Non‐Hodgkin's lymphomas, version 4.2014. J Natl Compr Cancer Netw. 2014;12(9):1282‐1303. 10.6004/jnccn.2014.0125 - DOI - PMC - PubMed
    1. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1‐2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981‐987. 10.1182/blood-2013-03-491514 - DOI - PMC - PubMed
    1. Luminari S, Manni M, Galimberti S, et al. Response‐adapted postinduction strategy in patients with advanced‐stage follicular lymphoma: the FOLL12 study. J Clin Oncol. 2022;40(7):729‐739. 10.1200/JCO.21.01234 - DOI - PubMed
    1. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first‐line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331‐1344. 10.1056/NEJMoa1614598 - DOI - PubMed

Publication types

LinkOut - more resources